Ethnic differences in pediatric systemic lupus erythematosus

Linda T Hiraki1, Susanne M Benseler, Pascal N Tyrrell

  • 1Division of Rheumatology, Hospital for Sick Children, University of Toronto, Toronto, Canada.

Insights

Pediatric systemic lupus erythematosus (pSLE) is more prevalent in non-Caucasian children, who are diagnosed younger and more often develop kidney disease. However, disease activity and damage are independent of ethnicity.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics and Epidemiology

Background:

  • Systemic lupus erythematosus (SLE) exhibits ethnic variations in adults, but this is less understood in pediatric SLE (pSLE).
  • Understanding ethnic disparities in pSLE is crucial for equitable healthcare and targeted interventions.

Purpose of the Study:

  • To compare the prevalence and severity of major organ involvement, disease activity, and damage in pediatric SLE across different ethnic groups.
  • To investigate the impact of ethnicity on the clinical presentation and disease course of pSLE.

Main Methods:

  • An inception cohort of 265 pediatric SLE patients at Sick Kids Hospital was analyzed.
  • Patients were categorized by self-designated ethnicity and compared to the Metropolitan Toronto at-risk population.
  • Longitudinal data on organ involvement, disease activity (SLE Disease Activity Index), and damage were collected and compared among ethnic groups.

Main Results:

  • Non-Caucasian patients constituted the majority (60%) of the pSLE cohort, a higher proportion than in the general population.
  • Non-Caucasian patients were diagnosed at a younger age (12.6 years) compared to Caucasian patients (14.6 years).
  • Renal disease (nephritis) was significantly more prevalent in non-Caucasian (62%) versus Caucasian (45%) pSLE patients.

Conclusions:

  • Non-Caucasian ethnicity is linked to a higher prevalence of pediatric SLE.
  • Younger age at diagnosis and increased likelihood of nephritis are associated with non-Caucasian ethnicity in pSLE.
  • Disease activity and damage in pSLE are primarily associated with major organ involvement, irrespective of patient ethnicity.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...